

# Hironori Koga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/390038/publications.pdf>

Version: 2024-02-01

62  
papers

2,320  
citations

257101

24  
h-index

214527

47  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound. <i>Cancer Reports</i> , 2022, 5, e1471.	0.6	7
2	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. <i>Cancer Reports</i> , 2022, 5, e1539.	0.6	3
3	Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells. <i>JGH Open</i> , 2022, 6, 270-273.	0.7	0
4	Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 575-579.	4.5	6
5	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. <i>Cancers</i> , 2022, 14, 2295.	1.7	3
6	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. <i>Cancers</i> , 2021, 13, 160.	1.7	38
7	Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 766-773.	0.9	3
8	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	1.7	19
9	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 987.	1.0	7
10	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. <i>Cancers</i> , 2021, 13, 2786.	1.7	44
11	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. <i>Cancers</i> , 2021, 13, 4450.	1.7	10
12	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. <i>Cancer Medicine</i> , 2021, 10, 8530-8541.	1.3	12
13	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2021, 13, 5282.	1.7	11
14	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. <i>Cancers</i> , 2020, 12, 1867.	1.7	56
15	Effects of canagliflozin on growth and metabolic reprogramming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). <i>PLoS ONE</i> , 2020, 15, e0232283.	1.1	32
16	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. <i>Nutrients</i> , 2020, 12, 1076.	1.7	27
17	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. <i>Cancers</i> , 2020, 12, 1010.	1.7	42
18	Promotion of liver regeneration and anti-fibrotic effects of the TGF $\beta$ 2 receptor kinase inhibitor galunisertib in CCl $_4$ -treated mice. <i>International Journal of Molecular Medicine</i> , 2020, 46, 427-438.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0232283.		0
20	Title is missing!. , 2020, 15, e0232283.		0
21	Title is missing!. , 2020, 15, e0232283.		0
22	Title is missing!. , 2020, 15, e0232283.		0
23	Title is missing!. , 2020, 15, e0232283.		0
24	Title is missing!. , 2020, 15, e0232283.		0
25	Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 580-588.	1.4	41
26	High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1046-1053.	1.8	21
27	Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. <i>Cancer Medicine</i> , 2019, 8, 2646-2653.	1.3	27
28	Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. <i>Medical Molecular Morphology</i> , 2019, 52, 198-208.	0.4	36
29	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. <i>Hepatology International</i> , 2019, 13, 293-301.	1.9	38
30	Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. <i>Hepatology Research</i> , 2019, 49, 479-486.	1.8	23
31	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. <i>Oncology</i> , 2019, 96, 192-199.	0.9	4
32	Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 56-64.	1.4	13
33	Ultrasound-guided central venous tip confirmation via right external jugular vein using a right supraclavicular fossa view. <i>Journal of Vascular Access</i> , 2019, 20, 19-23.	0.5	6
34	High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. <i>Cancer Science</i> , 2018, 109, 2801-2810.	1.7	63
35	Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. <i>Molecular Cancer Research</i> , 2017, 15, 744-752.	1.5	35
36	Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. <i>Journal of Hepatology</i> , 2017, 66, 142-152.	1.8	312

#	ARTICLE	IF	CITATIONS
37	Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1013-1020.	0.4	27
38	Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors. <i>Stem Cell Investigation</i> , 2016, 3, 37-37.	1.3	5
39	Ex vivo expansion of circulating CD34+ cells enhances the regenerative effect on rat liver cirrhosis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16025.	1.8	8
40	The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. <i>Journal of Critical Care</i> , 2016, 36, 29-34.	1.0	25
41	Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 243-250.	1.1	21
42	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. <i>Cancer Medicine</i> , 2015, 4, 1836-1843.	1.3	54
43	High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors. <i>Oncology Letters</i> , 2015, 10, 2015-2020.	0.8	15
44	Toxicity of Parasporin-4 and Health Effects of Pro-parasporin-4 Diet in Mice. <i>Toxins</i> , 2014, 6, 2115-2126.	1.5	5
45	Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis. <i>Hepatology International</i> , 2013, 7, 767-774.	1.9	23
46	New $\alpha$ -Lipoic Acid Derivative, DHL-HisZn, Ameliorates Renal Ischemia-Reperfusion Injury in Rats. <i>Journal of Surgical Research</i> , 2012, 174, 352-358.	0.8	25
47	Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor- $\kappa$ B/hypoxia-inducible factor-1 $\alpha$ axis under hypoxic conditions. <i>Hepatology Research</i> , 2012, 42, 591-600.	1.8	36
48	Loss of the SxxSS Motif in a Human T-Cell Factor-4 Isoform Confers Hypoxia Resistance to Liver Cancer: An Oncogenic Switch in Wnt Signaling. <i>PLoS ONE</i> , 2012, 7, e39981.	1.1	15
49	PPAR $\delta$ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. <i>International Journal of Oncology</i> , 2011, 40, 679-85.	1.4	18
50	Human Atrial Natriuretic Peptide Ameliorates LPS-Induced Acute Lung Injury in Rats. <i>Lung</i> , 2010, 188, 241-246.	1.4	9
51	Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. <i>Cancer</i> , 2008, 113, 2823-2831.	2.0	45
52	Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. <i>Journal of Hepatology</i> , 2007, 47, 93-102.	1.8	67
53	Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids. <i>Cancer Research</i> , 2006, 66, 4826-4834.	0.4	188
54	Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. <i>Hepatology</i> , 2003, 37, 136-147.	3.6	71

#	ARTICLE	IF	CITATIONS
55	Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. <i>Hepatology</i> , 2003, 37, 1086-1096.	3.6	58
56	Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. <i>Cancer</i> , 2003, 98, 661-667.	2.0	38
57	Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2003, 73, 230-235.	2.0	53
58	Abnormal accumulation in lipopolysaccharide in biliary epithelial cells of rats with self-filling blind loop. <i>International Journal of Molecular Medicine</i> , 2002, 9, 621.	1.8	10
59	Involvement of p21WAF1/CIP1 and p27KIP1 in Troglitazone-Induced Cell Cycle Arrest in Human Hepatoma Cell Lines. , 2002, , 61-72.		0
60	Abnormal accumulation in lipopolysaccharide in biliary epithelial cells of rats with self-filling blind loop. <i>International Journal of Molecular Medicine</i> , 2002, 9, 621-6.	1.8	16
61	Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. <i>Hepatology</i> , 2001, 33, 1087-1097.	3.6	141
62	Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. <i>Hepatology</i> , 1999, 29, 688-696.	3.6	395